amsacrine has been researched along with Vomiting in 7 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leukopenia was found to be dose-limiting; thrombocytopenia and anemia were also observed." | 1.26 | Phase II study of m-AMSA in advances malignant melanoma. ( Arseneau, JC; Kuperminc, M; Probert, JC; Wolter, JM, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hines, JD | 1 |
| Oken, MM | 1 |
| Mazza, JJ | 1 |
| Keller, AM | 1 |
| Streeter, RR | 1 |
| Glick, JH | 1 |
| Arlin, ZA | 1 |
| Dombernowsky, P | 1 |
| Siegenthaler, P | 1 |
| Somers, R | 1 |
| Hansen, HH | 1 |
| Arseneau, JC | 1 |
| Wolter, JM | 1 |
| Probert, JC | 1 |
| Kuperminc, M | 1 |
| Issell, BF | 1 |
| Sundström, GM | 1 |
| Wahlin, A | 1 |
| Willemze, R | 1 |
| Peters, WG | 1 |
| van Hennik, MB | 1 |
| Fibbe, WE | 1 |
| Kootte, AM | 1 |
| van Berkel, M | 1 |
| Lie, R | 1 |
| Rodenburg, CJ | 1 |
| Veltkamp, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amsacrine and Vomiting
| Article | Year |
|---|---|
Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1983 |
2 trials available for amsacrine and Vomiting
| Article | Year |
|---|---|
Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1983 |
Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Amsacrine; Antiemetics; Antineoplastic Combined Chemotherapy Protoco | 1997 |
5 other studies available for amsacrine and Vomiting
| Article | Year |
|---|---|
High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemother | 1984 |
Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinoma.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leuk | 1982 |
Phase II study of m-AMSA in advances malignant melanoma.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Drug Evaluation; Female; Humans; Leukopenia; Male; Melanoma; | 1982 |
Amsacrine (AMSA).
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Dogs; Dose-Response Rel | 1980 |
Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytara | 1985 |